# Novartis Pharmaceuticals clinical trials: 2,721 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 2,721 trials with Novartis Pharmaceuticals as lead sponsor, 209 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Novartis Pharmaceuticals: 2,721 rows for $107.21, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 11 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 2,721
- Recruiting or not yet: 209
- Read on: November 19, 2026

## Trials

The 25 newest of 2,721, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945548 | A Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine Learning... | Novartis Pharmaceuticals | Observational | Not yet recruiting | Breast Cancer | 8,001 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945548) |
| November 17, 2026 | NCT07940647 | A Safety and Tolerability Study of HJB647 in Adult Participants With Uncontrolled Hypertension | Novartis Pharmaceuticals | Phase 1 | Not yet recruiting | Uncontrolled Hypertension | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940647) |
| November 16, 2026 | NCT07938411 | A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction | Novartis Pharmaceuticals | Phase 3 | Not yet recruiting | Myocardial Infarction | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938411) |
| November 10, 2026 | NCT07928037 | A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic... | Novartis Pharmaceuticals | Observational | Not yet recruiting | Metastatic Castration-Resistant Prostate Cancer | 2,045 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928037) |
| November 6, 2026 | NCT07923773 | Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension) | Novartis Pharmaceuticals | Phase 2 | Not yet recruiting | Moderate to Severe Psoriatic Arthritis | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923773) |
| November 6, 2026 | NCT07923747 | An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE) | Novartis Pharmaceuticals | Phase 1 | Not yet recruiting | Rheumatoid Arthritis and Systemic Lupus Erythematosus | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923747) |
| November 5, 2026 | NCT07920315 | Remibrutinib in Real-world Clinical Practice - a South Korea Sub-Study | Novartis Pharmaceuticals | Observational | Not yet recruiting | Chronic Spontaneous Urticaria | 578 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920315) |
| November 2, 2026 | NCT07908680 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia | Novartis Pharmaceuticals | Phase 1 | Recruiting | Schizophrenia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908680) |
| November 2, 2026 | NCT07908667 | A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer | Novartis Pharmaceuticals | Phase 1 | Recruiting | Extensive-stage Small Cell Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908667) |
| October 27, 2026 | NCT07896746 | Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda | Novartis Pharmaceuticals | Observational | Not yet recruiting | Malaria | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896746) |
| October 22, 2026 | NCT07889310 | Managed Access Programs for MAS825, Arumakimig | Novartis Pharmaceuticals | Not applicable | Temporarily not available | Still's Disease, Including SJIA and AOSD, With MAS or ILD Complications | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889310) |
| October 19, 2026 | NCT07881783 | A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without... | Novartis Pharmaceuticals | Observational | Not yet recruiting | Plaque Psoriasis | 3,718 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881783) |
| October 9, 2026 | NCT07868328 | A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies | Novartis Pharmaceuticals | Phase 2 | Not yet recruiting | Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868328) |
| October 2, 2026 | NCT07855276 | A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS | Novartis Pharmaceuticals | Phase 1 | Recruiting | Hidradenitis Suppurativa | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855276) |
| September 30, 2026 | NCT07850752 | A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy | Novartis Pharmaceuticals | Phase 3 | Not yet recruiting | IgA Nephropathy (IgAN) | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850752) |
| September 28, 2026 | NCT07844070 | A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After Pregnancy | Novartis Pharmaceuticals | Observational | Active not recruiting | Multiple Sclerosis | 2,607 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844070) |
| September 28, 2026 | NCT07843758 | An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With... | Novartis Pharmaceuticals | Observational | Completed | Castration-Resistant Prostatic Cancer | 1,525 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843758) |
| September 24, 2026 | NCT07839858 | A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France | Novartis Pharmaceuticals | Observational | Completed | Polycythemia Vera | 237 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839858) |
| September 21, 2026 | NCT07830719 | Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | Novartis Pharmaceuticals | Phase 2 | Recruiting | Coronary Artery Disease | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830719) |
| September 15, 2026 | NCT07821411 | A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan | Novartis Pharmaceuticals | Observational | Active not recruiting | Multiple Sclerosis | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821411) |
| September 11, 2026 | NCT07816328 | Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately... | Novartis Pharmaceuticals | Phase 3 | Recruiting | Chronic Spontaneous Urticaria | 382 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816328) |
| September 10, 2026 | NCT07811908 | Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria... | Novartis Pharmaceuticals | Phase 2 | Recruiting | Uncomplicated Plasmodium Falciparum Malaria | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811908) |
| September 10, 2026 | NCT07811882 | Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria... | Novartis Pharmaceuticals | Phase 2 | Completed | Uncomplicated Plasmodium Falciparum Malaria | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811882) |
| September 10, 2026 | NCT07811869 | A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin... | Novartis Pharmaceuticals | Phase 3 | Recruiting | Chronic Pruritus of Unknown Origin | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811869) |
| September 9, 2026 | NCT07809919 | A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects | Novartis Pharmaceuticals | Phase 1 | Completed | Visceral Leishmaniasis, Chagas Disease | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809919) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 2 |
| Phase 1 | 406 |
| Phase 1/2 | 111 |
| Phase 2 | 704 |
| Phase 2/3 | 28 |
| Phase 3 | 712 |
| Phase 4 | 343 |
| Not applicable | 52 |
| Observational | 363 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 1,839 |
| Terminated | 377 |
| Recruiting | 180 |
| Active not recruiting | 155 |
| Withdrawn | 97 |
| Not yet recruiting | 29 |
| No longer available | 28 |
| Available | 13 |
| Approved for marketing | 2 |
| Temporarily not available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 165 |
| Neoplasms | 100 |
| Carcinoma, Non-Small-Cell Lung | 91 |
| Pulmonary Disease, Chronic Obstructive | 88 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 82 |
| Multiple Sclerosis | 74 |
| Asthma | 73 |
| Diabetes Mellitus, Type 2 | 69 |
| Hypertension | 63 |
| Prostatic Neoplasms | 52 |
| Recurrence | 50 |
| Psoriasis | 49 |
| Heart Failure | 46 |
| Melanoma | 45 |
| Neoplasm Metastasis | 43 |
| Macular Degeneration | 43 |
| Leukemia, Myeloid, Acute | 40 |
| Lung Neoplasms | 38 |
| Chronic Urticaria | 37 |
| Myelodysplastic Syndromes | 36 |
| Carcinoma, Renal Cell | 35 |
| Multiple Myeloma | 34 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 32 |
| Leukemia | 31 |
| Iron Overload | 31 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Soup restaurants in the United States](https://specstream.ai/data/businesses/soup-restaurants/united-states)
- [Business financing companies in the United States](https://specstream.ai/data/businesses/business-financing-companies/united-states)
- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
- [Sand and gravel suppliers in the United States](https://specstream.ai/data/businesses/sand-and-gravel-suppliers/united-states)
- [Bed and breakfasts in the United States](https://specstream.ai/data/businesses/bed-and-breakfasts/united-states)
